Shares of Bausch Health Companies Inc. (TSE:BHC - Get Free Report) traded up 8.4% during mid-day trading on Thursday following a better than expected earnings announcement. The company traded as high as C$12.37 and last traded at C$12.33. 36,968 shares were traded during trading, a decline of 90% from the average session volume of 370,617 shares. The stock had previously closed at C$11.37.
The company reported C$1.53 earnings per share (EPS) for the quarter, topping the consensus estimate of C$1.43 by C$0.10. The business had revenue of C$3.42 billion for the quarter, compared to analyst estimates of C$3.36 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 2,304.54%.
Wall Street Analysts Forecast Growth
Several research firms have commented on BHC. Raymond James upgraded Bausch Health Companies to a "hold" rating in a research note on Wednesday, July 10th. Evercore ISI upgraded shares of Bausch Health Companies to a "hold" rating in a report on Tuesday, October 15th.
View Our Latest Stock Analysis on BHC
Insider Activity at Bausch Health Companies
In related news, Senior Officer Seana Lynne Carson sold 13,370 shares of the firm's stock in a transaction on Friday, September 6th. The stock was sold at an average price of C$8.38, for a total transaction of C$112,087.40. Company insiders own 11.28% of the company's stock.
Bausch Health Companies Stock Performance
The company has a market cap of C$4.70 billion, a P/E ratio of -7.09, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77. The company has a quick ratio of 0.58, a current ratio of 1.19 and a debt-to-equity ratio of 7,583.76. The stock's 50-day moving average price is C$9.82 and its 200 day moving average price is C$9.87.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Articles
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
